FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Results

Title:	FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.
Authors:	Siefker-Radtke, Arlene O; Currie, Graeme; Abella, Esteban; Vaena, Daniel A; Kalebasty, Arash Rezazadeh; Curigliano, Giuseppe; Tupikowski, Krzysztof; Andric, Zoran G ; Lugowska, Iwona; Kelly, William Kevin
Issue Date:	2019
Publication:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Search Idenfier
Type:	Conference Paper
Collation:	vol. 37 br. 15 str. 4511-4511
DOI:	10.1200/JCO.2019.37.15_suppl.4511
WoS-ID:	000487345805337
URI:	https://enauka.gov.rs/handle/123456789/821434
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

39
OpenCitations

47
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall

Google Scholar^TM